
BACKGROUND Canada eliminated measles in 1998; however, large outbreaks have been recently reported, and elimination status was lost in 2025. AIM We aimed to estimate the effect of age at first dose of measles-containing vaccine (MCV1) on measles IgG concentration and seronegativity among two-dose recipients nearly two decades after vaccination. METHODS We conducted a retrospective cohort study of 10,766 twice-vaccinated individuals tested for measles IgG from 2014 to 2016 in Ontario, Canada. We predicted measles IgG concentration and seronegativity using thresholds of < 275 mIU/mL, < 200 mIU/mL and ≤ 120 mIU/mL. RESULTS A 1-month increase in age at MCV1 (between 12 and 15 months) was associated with 13.7% (95% confidence interval (CI): 7.1–20.8) higher predicted mean measles IgG concentration for females born after elimination and 9.2% (95% CI: 6.8–11.6) for females born before elimination. Depending on the seronegativity threshold and the measles elimination status at birth, a 1-month increase in age at MCV1 (between 12 and 15 months) was associated with lower odds ratio of seronegativity ranging from 0.74 (95% CI: 0.63–0.85) to 0.87 (95% CI: 0.57–1.27). Using the lowest threshold (≤ 120 mIU/mL) and the longest follow-up period (24 years post-MCV1), we predicted that 4.1% (95% CI: 2.7–6.1) of females vaccinated with MCV1 at 15 months of age would be seronegative, compared with 9.6% (95% CI: 7.4–12.3) of those vaccinated at 12 months. DISCUSSION Delaying MCV1 to older ages (13–15 months) may result in an absolute decrease as large as 6% in the percentage of seronegative individuals, potentially increasing the likelihood of maintaining herd immunity.
BACKGROUND Diphtheria is a rare vaccine-preventable disease in Germany, but since 2022 Corynebacterium diphtheriae cases have increased following an outbreak among newly arriving migrants. AIM We described epidemiological trends and differences between C. diphtheriae and C. ulcerans cases. METHODS We included laboratory-confirmed (toxigenic or tox gene positive) diphtheria cases and cases epidemiologically linked to laboratory-confirmed cases in Germany in 2017–2025. Enhanced surveillance data were available for a subset of cases in 2017–2022. We analysed cases by species assessing clinical, demographic and epidemiological characteristics descriptively, with chi-square and Fisher’s exact tests. RESULTS Overall, 512 diphtheria cases were reported (346 C. diphtheriae; 166 C. ulcerans; incidence: 0.07/100,000 population) including five deaths (three C. diphtheriae, two C. ulcerans, all reported since 2022). Of these, 460 (90%) cases had cutaneous, 30 (6%) respiratory and 22 (4%) double manifestation. Four epidemiological phases were identified. Acquisition of C. diphtheriae shifted from predominantly migration-associated (232/261) in 2022–2023 to autochthonous transmission (35/54) in 2024–2025. Autochthonous C. diphtheriae cases were older and more often hospitalised than imported cases (≥ 45 years: 23/45 vs 19/283; p < 0.001; hospitalisation: 36/45 vs 83/283; p < 0.001). All C. ulcerans cases were autochthonous and 70 of 89 (79%) reported contact with companion animals. CONCLUSION Diphtheria is re-emerging in Germany. Double manifestations warrant attention, being almost as common as respiratory manifestations. Clinicians should be aware of the disease to facilitate prompt diagnosis and treatment. Preventing severe cases and further transmission requires strengthening routine and catch-up vaccination services, particularly for older individuals and people experiencing homelessness.
BACKGROUND Between October 2023 and September 2024, England experienced the largest measles outbreak in decades. AIM We describe the epidemiology of the outbreak, burden on secondary care services and the factors that led to this resurgence. METHODS The UK Health Security Agency (UKHSA) conducts enhanced surveillance of all suspected measles cases in England. A measles line list was established using routinely collected notification, laboratory, demographic and vaccination information. Laboratory-confirmed cases were defined using serology and PCR. Incidence rates were calculated using mid-2024 population estimates. Severity was assessed through linkage with emergency department attendances, hospital admissions and length of stay. RESULTS Most of the 2,821 laboratory-confirmed cases resided in London (n = 1,283; 45.5%) and in the West Midlands (n = 710; 25.2%). Incidence was highest in London (14.1/100,000 population). Children under 10 years represented 58.6% (n = 1,653) of cases. Most cases (n = 2,609; 92.5%) were not vaccinated, and 63.0% (n = 1,776) lived in areas belonging to the two most deprived quintiles. Of the 2,788 cases that could be linked to hospitalisation data, 76.3% (n = 2,127) attended emergency care and 38.2% (n = 1,066) were admitted. Median length of stay was 2.0 days, seven cases received intensive care; one death was reported. Admissions were highest among infants aged < 1 year (51.6%, 165/320) and adults ≥ 30 years (47.2%, 195/413). CONCLUSION This outbreak reflects a shift towards endemic measles transmission in areas of high deprivation and low vaccine uptake in England. It underscores the importance of achieving 95% uptake with measles vaccine in all areas and communities to achieve and maintain elimination.
BACKGROUND Following substantial progress towards measles elimination after the COVID-19 pandemic, Italy experienced a marked increase in measles cases in 2024. AIM Our aim was to describe measles epidemiology in Italy, October 2023–March 2025, and assess vaccination coverage, surveillance performance at national and regional levels, and temporal patterns of transmission. METHODS Numbers of measles cases and outbreaks were reviewed. Vaccination coverage and surveillance indicators were described at national and regional levels. Measles variants were classified by genotype and Distinct Sequence Identifier (DSId). Temporal transmission patterns of measles variants were assessed nationally and regionally to identify sustained transmission chains (≥ 12 consecutive months). RESULTS In total, 1,311 measles cases were reported, with 178 outbreaks. Cases’ median age was 30.9 years (IQR: 15.6–39.8); 601 were female (45.8%) and 710 male (54.2%). Only 3.1% (38/1,230) were fully vaccinated. In 2024, the first-dose vaccination coverage increased to 94.77% (95% CI: 94.70–94.84%) nationally, while second-dose coverage declined to 84.45% (95% CI: 84.35–84.55%). Among all cases, 12.1% (n = 158) were imported/importation-related, 64.1% (n = 841) were of unknown origin and 52.8% had DSId data available (n = 692), with high regional heterogeneity. Twenty-five measles variants were identified. One variant (D8–5963) showed sustained national transmission for over 12 months, meeting criteria for re-established endemic transmission, although no single region showed uninterrupted ≥ 12-month circulation. CONCLUSION Measles resurgence in Italy was marked by persistent immunity gaps, heterogeneous surveillance performance, and sustained national circulation of a D8 variant, indicating loss of near-elimination status. Strengthening vaccination strategies and enhancing molecular surveillance is urgently needed to restore progress towards measles elimination.